BillionToOne, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- BillionToOne, Inc. (Nasdaq: BLLN) develops and commercializes precision molecular diagnostics using its proprietary Quantitative Counting Templates (QCT) platform, which enables single-molecule DNA counting for prenatal screening and oncology applications; primary products include UNITY Screen and UNITY Complete, non-invasive prenatal tests (NIPT) assessing fetal risks for aneuploidies, recessive conditions, and fetal antigens from a single maternal blood draw at 9+ weeks gestation; Northstar Select, a liquid biopsy test for therapy selection via detection of tumor mutations including deletions, insertions, and point mutations; and Northstar Response, a complementary liquid biopsy for real-time cancer burden monitoring through methylation assessment. The company operates primarily in the United States, targeting obstetricians, gynecologists, oncologists, and healthcare networks with broad payer coverage; it was founded in 2016 and maintains headquarters in Menlo Park, California. Recent developments encompass a $314 million upsized initial public offering completed in November 2025, with shares trading under BLLN; a $130 million oversubscribed Series D funding round in June 2024 achieving over $1 billion valuation; expanded Medicare access via MolDx approval for Northstar Select in April 2025; launch of a 14-gene UNITY Fetal Risk Screen in May 2025; surpassing 500 employees and one million UNITY tests by November 2024 and March 2025, respectively; and a global collaboration with Johnson & Johnson announced in December 2023 for UNITY Fetal Antigen in a Phase 3 trial of nipocalimab for hemolytic disease of the fetus and newborn.
Are Medical Stocks Lagging BillionToOne, Inc. (BLLN) This Year?
BillionToOne's Northstar Response® Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-of-Care Imaging for Cancer Patients in Peer-Reviewed Study
BillionToOne's Northstar Response® Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-of-Care Imaging for Cancer Patients in Peer-Reviewed Study
Is BillionToOne, Inc. (BLLN) Stock Outpacing Its Medical Peers This Year?
BillionToOne to Participate in the William Blair 46th Annual Growth Stock Conference
Baron Health Care Fund Q1 2026 Portfolio Activity
Does BillionToOne (BLLN) Have the Potential to Rally 37% as Wall Street Analysts Expect?
Wall Street Analysts Predict a 25.63% Upside in BillionToOne (BLLN): Here's What You Should Know
BillionToOne (BLLN) Reports Q1 Earnings: What Key Metrics Have to Say
BillionToOne Reports First Quarter 2026 Results and Raises 2026 Revenue Guidance
BillionToOne Launches Unity Confirm™: A category-defining test that bridges the gap between screening and invasive diagnostics
BillionToOne Appoints Dr. Allen Chen as Vice President of Medical Affairs and Clinical Development, Oncology
Billiontoone, Inc. (NASDAQ:BLLN) Given Consensus Rating of “Moderate Buy” by Analysts
BillionToOne, Inc. (BLLN) Q4 2025 Earnings Call Transcript
BillionToOne: Delivering And Lagging At The Same Time
Billiontoone (NASDAQ:BLLN) Sees Large Volume Increase After Earnings Beat
BillionToOne (BLLN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue Guidance
BillionToOne to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
Reviewing Advanced Biomed (NASDAQ:ADVB) & Billiontoone (NASDAQ:BLLN)